Adverse effects: 4b. Other ‐ average endpoint weight loss (average weight in kg) (skewed) | ||||
---|---|---|---|---|
Study | Intervention | Mean(kg) | SD | N |
short term (up to 12 weeks) | ||||
Conley 2005 | Fluphenazine | ‐2.6 | 5.7 | 13 |
Conley 2005 | Risperidone | ‐0.65 | 2.43 | 13 |
Adverse effects: 4b. Other ‐ average endpoint weight loss (average weight in kg) (skewed) | ||||
---|---|---|---|---|
Study | Intervention | Mean(kg) | SD | N |
short term (up to 12 weeks) | ||||
Conley 2005 | Fluphenazine | ‐2.6 | 5.7 | 13 |
Conley 2005 | Risperidone | ‐0.65 | 2.43 | 13 |